{"product_id":"progyny-five-forces-analysis","title":"Progyny Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis brief snapshot highlights key competitive pressures facing Progyny across buyer power, supplier influence, and substitute threats. It surfaces strategic vulnerabilities and growth levers but stops short of full diagnostics. Unlock the full Porter’s Five Forces Analysis for data-driven ratings, visuals, and actionable recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated fertility clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProgyny relies on a curated network of regionally concentrated, capacity-constrained high-performing fertility clinics, giving top clinics leverage over pricing and referral allocation. Progyny’s ability to steer volume toward preferred providers and publish outcomes data provides counter-leverage that helps contain costs. Multi-year contracts and performance tiers further temper rate escalation by locking rates and tying pricing to outcomes. This dynamic creates negotiated, outcome-linked pricing power on both sides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty fertility drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty fertility drugs like gonadotropins are produced by a concentrated group of manufacturers, keeping supplier power elevated in 2024 and making supply tightness a persistent risk.\u003c\/p\u003e\n\u003cp\u003eLimited therapeutic substitutes and episodic shortages can drive up per-cycle medication costs, which often comprise a large share of overall IVF spending.\u003c\/p\u003e\n\u003cp\u003eProgyny leverages its integrated pharmacy benefit to negotiate rebates, manage adherence, and use formulary and clinical protocols to blunt price shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLab tech and equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmbryology lab platforms, genetic testing, and cryostorage systems create high switching frictions and vendor lock-in for Progyny, with leading equipment vendors capturing roughly 50%+ of market supply in 2024 and multi-year service contracts common. Vendors exert leverage via service contracts and staggered upgrade cycles that drive recurring capital and O\u0026amp;M spend. Standardizing interfaces and using outcome-based vendor scorecards can reduce dependency, while scale procurement and data-sharing partnerships improve pricing and service terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData and outcomes dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinic partners hold proprietary outcomes data that underpins Progyny’s differentiated value, and while 2024 data-sharing clauses and interoperability commitments increased compliance, they remain legally contestable. Progyny’s analytics and benchmark reporting create mutual value, reducing supplier leverage by aligning incentives. Growing use of claims, pharmacy feeds and patient-reported outcomes diversifies data reliance and lowers supplier concentration risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData control: clinic-owned outcomes\u003c\/li\u003e\n\u003cli\u003eLegal risk: contestable sharing clauses\u003c\/li\u003e\n\u003cli\u003eValue offset: analytics\/benchmarks\u003c\/li\u003e\n\u003cli\u003eDiversification: claims, pharmacy, PROs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and accreditation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompliance with ASRM, CAP, and roughly 20 state infertility coverage mandates in 2024 constrains clinic supply flexibility and raises switching costs for buyers. Over 8,000 CAP-accredited labs can demand preferred status and pricing, and accredited clinics often command premium rates. Progyny leverages accreditation as a quality gate tied to reimbursement and performance, while expanding state mandates can shift power toward aggregators and payers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003e~20 states with infertility mandates (2024)\u003c\/li\u003e\n\u003cli\u003e8,000+ CAP-accredited labs\u003c\/li\u003e\n\u003cli\u003eAccreditation used by Progyny to negotiate performance-based rates\u003c\/li\u003e\n\u003cli\u003ePolicy shifts increase aggregator leverage\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh supplier power from clinics and 8,000+ CAP labs; volume steering and data reduce risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProgyny faces elevated supplier power from regionally concentrated top clinics, 8,000+ CAP-accredited labs, and specialty drug manufacturers (top 3 dominate supply in 2024), but counters with volume steering, multi-year outcome-linked contracts, integrated pharmacy rebates, and analytics that reduce dependence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStates with mandates\u003c\/td\u003e\n\u003ctd\u003e~20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAP labs\u003c\/td\u003e\n\u003ctd\u003e8,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop vendor share\u003c\/td\u003e\n\u003ctd\u003e50%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Progyny that uncovers competitive drivers, buyer\/supplier power, threat of substitutes and new entrants, and identifies disruptive forces and strategic levers to protect market share; editable Word-ready format for investor decks, business plans, and internal strategy use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, one-sheet Porter's Five Forces for Progyny that distills competitive pressures into a single, shareable view—ideal for fast strategic decisions. Customize force levels, swap data, and drop the radar chart straight into pitch decks or board materials without complex tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge self-insured employers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge self-insured employers (often \u0026gt;1,000 lives) run competitive RFPs, driving price pressure and supplier consolidation; 70% of buyers in 2024 cited outcomes and ROI as top selection criteria. They benchmark vendors on clinical outcomes, member experience, and cost per live birth; multi-year, performance-linked contracts (typically 3–5 years) align incentives. Custom plan design and analytics dashboards are key negotiation levers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth plans and ASOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayers can bundle or carve-in fertility benefits and negotiate aggressive rates and integrations, leveraging distribution to employers that cover roughly 155 million Americans under employer-sponsored plans (KFF 2023), boosting their bargaining power. White-label partnerships allow payers to trade margin for volume, pressuring specialty vendors on price and scale. Deep EDI integration and proven utilization controls, however, strengthen Progyny’s negotiating stance by reducing administrative friction and demonstrating cost containment. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching ease across vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBenefits platforms enable comparative shopping at annual renewals, making vendor swaps more visible, while implementation timelines and member disruption create moderate switching costs; documented clinical outcomes and strong member NPS materially reduce churn, and explicit data portability and continuity-of-care assurances further lower perceived risk of switching or staying.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcurement sophistication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHR teams, benefits consultants and PBMs now bring predictive analytics and industry benchmarks into Progyny negotiations, shifting leverage toward buyers who demand guarantees, SLAs and outcome reporting; value-based pricing and case-rate predictability blunt pure price bidding and improve margin visibility; referenceable logos and third-party validations materially raise win rates in competitive RFPs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProcurement sophistication: analytics-led negotiations\u003c\/li\u003e\n\u003cli\u003eBuyer demands: guarantees, SLAs, outcomes\u003c\/li\u003e\n\u003cli\u003ePricing: value-based, case-rate over price-only\u003c\/li\u003e\n\u003cli\u003eSales levers: referenceable logos, third-party validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMember voice and utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMember voice and utilization drive employer bargaining power: in 2024 employers cite inclusive family-building benefits as a top demand factor when selecting carriers, so high member engagement lets Progyny justify richer packages that blunt buyer price pressure. Poor access or subpar outcomes prompt plan redesigns and rapid contract renegotiation. Robust navigation and concierge support sustain perceived value and reduce churn.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMember-driven demand: inclusion influences employer choice\u003c\/li\u003e\n\u003cli\u003eHigh utilization supports premium offerings, lowers price sensitivity\u003c\/li\u003e\n\u003cli\u003eNegative outcomes trigger plan redesigns and contract leverage\u003c\/li\u003e\n\u003cli\u003eConcierge\/navigation services preserve retention and perceived ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutcomes-driven buying reshapes employer RFPs: 155M lives, 3–5yr performance deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge self-insured employers (often \u0026gt;1,000 lives) run RFPs, driving price pressure and consolidation; 70% of buyers in 2024 prioritized outcomes and ROI. Payers leverage access to ~155 million covered by employer plans (KFF 2023) to negotiate rates; multi-year, performance-linked contracts (3–5 years) are common. Strong outcomes, NPS and integrations reduce churn and raise Progyny’s bargaining power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eSource\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuyers citing outcomes\/ROI\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003ctd\u003e2024 survey\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmericans under employer plans\u003c\/td\u003e\n\u003ctd\u003e~155M\u003c\/td\u003e\n\u003ctd\u003eKFF 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical contract length\u003c\/td\u003e\n\u003ctd\u003e3–5 years\u003c\/td\u003e\n\u003ctd\u003eMarket data 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eProgyny Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Progyny Porter's Five Forces Analysis you'll receive after purchase—no placeholders or mockups. The document is the full, professionally formatted analysis of competitive forces, ready to download and use immediately. Instant access is granted upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eivalry Among Competitors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCarrot Fertility, WINFertility, Kindbody and Maven Clinic compete aggressively on network size, care navigation and pricing, while differentiation hinges on outcomes data, integrated pharmacy services and breadth of modalities offered. Vertical integration, notably owned clinics and in‑house labs, intensifies rivalry by locking employer contracts and improving unit economics. Regional depth and employer vertical expertise drive win rates in major accounts, forcing continuous investment in data and service breadth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and PBM encroachment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealth plans and PBMs are embedding fertility solutions into medical and pharmacy benefits, leveraging existing employer relationships and claims data to drive utilization and cost control. The three largest PBMs processed roughly 80% of U.S. prescriptions in 2024, amplifying their negotiating power. Progyny counters with specialized clinical protocols and a superior member experience focused on outcomes and fertility success rates. Co-opetition via carve-ins or network access blurs vendor lines and raises integration stakes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutcome-led differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProgyny’s outcome-led differentiation—notably lower multiple-birth rates (~5–10% vs ~20–25% in many ART cohorts), higher singleton live-birth rates (~50–60% per intended treatment) and fewer cycles per live birth (~1.3–1.6)—forms a strong moat; competitors lean on price or convenience when they cannot match these outcomes. Transparent reporting and third-party validation sustain premium pricing, while continuous protocol refinement (ongoing RCTs and registry updates) raises the clinical bar.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and data platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNavigation apps, predictive analytics and care-coordination tools are table stakes; rivals now add AI triage, adherence nudges and cost-forecasting to differentiate. Interoperability with EMR and pharmacy systems (driven by ONC rules and APIs) creates customer stickiness and operational lock-in. Data network effects from aggregated outcomes and claims data can yield durable advantages for firms like Progyny.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAI triage \u0026amp; nudges\u003c\/li\u003e\n\u003cli\u003eCost forecasting\u003c\/li\u003e\n\u003cli\u003eEMR\/pharmacy interoperability\u003c\/li\u003e\n\u003cli\u003eData network effects → stickiness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice-based bidding dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRFPs drive aggressive price-based bidding that compresses margins via per-employee-per-month and case-rate pressure, with 2024 procurement processes increasingly demanding bundled guarantees that intensify head-to-head competition. Proven outcomes enable Progyny to shift negotiations toward value-based constructs that defend price. Multi-product bundling across fertility, maternity and menopause changes the competitive basis from unit price to holistic program value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePEPM and case-rate pressure\u003c\/li\u003e\n\u003cli\u003eBundled guarantees raise bid intensity\u003c\/li\u003e\n\u003cli\u003eValue-based pricing protects margins\u003c\/li\u003e\n\u003cli\u003eMulti-product bundling shifts competition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutcome-focused fertility managers: better singleton outcomes, PBM integration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntense rivaling on network scale, price and navigation meets Progyny’s outcome moat—multiple-births ~5–10% vs 20–25% market, singleton live-births ~50–60% per intended treatment and cycles per live birth ~1.3–1.6. PBMs processed ~80% of U.S. scripts in 2024, raising integration risk. RFP-driven PEPM\/case-rate bidding compresses margins; value-based guarantees and bundling shift competition to outcomes and total-program value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eProgyny\u003c\/th\u003e\n\u003cth\u003eMarket\/2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMultiple-birth rate\u003c\/td\u003e\n\u003ctd\u003e5–10%\u003c\/td\u003e\n\u003ctd\u003e20–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingleton LBR\u003c\/td\u003e\n\u003ctd\u003e50–60%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCycles per live birth\u003c\/td\u003e\n\u003ctd\u003e1.3–1.6\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM script share\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eSubstitutes Threaten\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional insurance coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmployers may rely on standard health plan coverage without a specialized carve-out, substituting comprehensive navigation with basic benefits despite fertility affecting about 1 in 6 couples globally. Basic plans can drive higher downstream costs given average US IVF costs of roughly $15,000–20,000 per cycle in 2024 and poorer outcomes without care management. Reduced vendor complexity is appealing, so strong ROI proof from specialty vendors is required to prevent reversion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-clinic cash programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMembers increasingly use direct-to-clinic cash programs and discount bundles, bypassing employer navigation and pharmacy integration; studies through 2024 show out-of-network leakage materially rising in fertility markets. Employers must invest in education and steerage to retain utilization in-network. Transparent pricing and proven superior outcomes are proven levers to reduce leakage and protect benefit ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative family-building paths\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdoption, foster-to-adopt and surrogacy can substitute for IVF; CDC data show 306,197 assisted reproductive technology cycles in the US in 2019 while AFCARS reports roughly 63,000 adoptions from foster care annually, indicating meaningful alternative flows. Benefits allocation across paths materially influences member choice, and Progyny’s inclusive coverage reduces substitution risk by embracing alternatives. Personalized counseling aligns member decisions with clinical odds and out-of-pocket costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital-only wellness solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneric telehealth and fertility tracking apps are often perceived as good enough for initial guidance, but they lack end-to-end clinical management and pharmacy integration that drive outcomes; CDC data shows IVF live-birth rates can exceed 40% for women under 35, underscoring the importance of clinical pathways.\u003c\/p\u003e\n\u003cp\u003eEmbedding digital tools within a full clinical pathway counters this threat by maintaining care coordination and medication adherence, preserving differentiation through demonstrated improved live-birth outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubstitute risk: high user adoption but limited clinical depth\u003c\/li\u003e\n\u003cli\u003eKey gap: no integrated pharmacy or lab workflow\u003c\/li\u003e\n\u003cli\u003eDefense: measurable live-birth improvement (\u0026gt;40% in \u0026lt;35 per CDC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternal navigation by employers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLarge employers increasingly build in-house navigation or adopt benefits platforms to manage fertility care; by 2024 over 50% of large employers offered some fertility benefits. Replicating Progyny’s clinic networks, pharmacy integration and outcomes management demands high capital, vendor contracts and clinical\/regulatory expertise, driving total cost and compliance risk. Co-sourcing models can convert potential substitution into partnership, preserving scale and data advantages.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: \u0026gt;50% large employers offer fertility benefits\u003c\/li\u003e\n\u003cli\u003eUS IVF cost range 12,000–20,000 per cycle (2024)\u003c\/li\u003e\n\u003cli\u003eCo-sourcing reduces upfront build cost and compliance burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Arrows-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIVF substitution risk high; employers and outcomes data curb leakage, costs \u003cstrong\u003e$15–20k\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSubstitute threat is moderate-high: cash clinics, D2C apps and adoption\/surrogacy divert users despite fertility affecting ~1 in 6 couples and US IVF cost ~$15–20k per cycle (2024). Employers offering benefits (\u0026gt;50% large employers, 2024) can steer utilization; Progyny’s integrated pharmacy, clinic network and outcomes data (\u0026gt;40% live-birth \u0026lt;35) mitigate leakage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003cth\u003eRelevance\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIVF cost\u003c\/td\u003e\n\u003ctd\u003e$15–20k\/cycle\u003c\/td\u003e\n\u003ctd\u003edrives cash substitution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLarge employers w\/benefits\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50%\u003c\/td\u003e\n\u003ctd\u003eemployer steerage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLive-birth \u0026lt;35\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40%\u003c\/td\u003e\n\u003ctd\u003eoutcome differentiation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003entrants Threaten\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital health startups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLow software barriers let new navigation apps and coaching services launch quickly, but winning requires clinic networks, pharmacy contracting, and robust outcomes proof. Entrants face long enterprise sales cycles often spanning 9–18 months and stringent RFPs that demand clinical and cost-effectiveness data. Capital needs rise materially when offering guarantees or value-based pricing, increasing financing and actuarial requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinic-led integrated offerings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinic groups launching employer-facing bundles can capture margin in a global fertility market valued at about $26.7 billion in 2024, but limited geographic reach and perceived provider bias constrain employer adoption; building multi-clinic, outcomes-validated networks remains a significant hurdle, making Progyny’s neutral, payer-agnostic positioning a competitive advantage for employers seeking unbiased, network-wide outcomes coordination.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer\/PBM packaged solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIncumbent payers and PBMs can cross-sell fertility into large existing books, leveraging claims scale and clinical data to negotiate pricing and steer referrals; top three PBMs manage roughly 80% of US prescription scripts (2024). For Progyny, differentiation on member experience and measurable outcomes is critical to resist commoditization. Strategic partnerships or carve-in models with payers can preempt displacement by embedding Progyny services into benefit designs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory tailwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpregulatory tailwinds in have expanded the addressable fertility market as new state mandates and tax incentives encourage employer public coverage drawing potential entrants but strict hipaa clinical-quality accreditation data-privacy requirements increase operating complexity cost. established payer protocols mandatory reporting soc expectations create meaningful barriers rigorous vendor risk management standards filter newcomers based on compliance clinical outcomes.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e2024 market pull: state mandates and tax incentives increase demand\u003c\/li\u003e\u003cli\u003eCompliance: HIPAA, SOC 2, HITRUST raise entry costs\u003c\/li\u003e\u003cli\u003eClinical reporting: mandatory protocols\/reporting systems act as barriers\u003c\/li\u003e\u003cli\u003eVendor risk management: strict standards screen entrants\u003c\/li\u003e\n\u003c\/pregulatory\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching and brand trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEntrants must overcome employer risk aversion and member trust; Progyny's proven outcomes, client references, and EHR\/payor integration capabilities are table stakes. Migration costs and continuity-of-care concerns—given average US IVF cost about 20,000 per cycle (2024)—deter switching. Track record and national scale remain durable entry barriers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eEmployer risk aversion\u003c\/li\u003e\n\u003cli\u003eMember trust requirement\u003c\/li\u003e\n\u003cli\u003eProven outcomes \u0026amp; references\u003c\/li\u003e\n\u003cli\u003eIntegration\/IT chops\u003c\/li\u003e\n\u003cli\u003eHigh migration costs (~20,000\/cycle)\u003c\/li\u003e\n\u003cli\u003eContinuity-of-care concerns\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Lamp-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApp entrants face clinic, pharmacy and compliance hurdles in $26.7B fertility market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLow tech barriers enable app\/coaching entrants, but clinic networks, pharmacy contracting, 9–18 month enterprise sales and capital for guarantees raise hurdles. State mandates and $26.7B global fertility market (2024) attract entrants, yet HIPAA\/SOC2\/HITRUST and vendor-risk standards limit viable competitors.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003e$26.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales cycle\u003c\/td\u003e\n\u003ctd\u003e9–18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg IVF cost\u003c\/td\u003e\n\u003ctd\u003e$20,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098202247516,"sku":"progyny-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/progyny-five-forces-analysis.png?v=1781803784","url":"https:\/\/pestel-analysis.com\/products\/progyny-five-forces-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}